Early evolocumab after a heart attack: faster LDL-C lowering, no one-year outcome benefit

Table of Contents

1.0 Summary

In the AMUNDSEN randomized trial, 2,161 people with STEMI or NSTEMI undergoing urgent coronary stenting received evolocumab before the procedure plus standard care, or standard care alone. Evolocumab produced much lower LDL-C levels and more patients reached the study’s LDL-C goal, but the one-year rate of death or unplanned cardiovascular hospitalization was similar between groups. The report is a secondary ACC analysis of the trial, follow-up lasted one year, and the control group could receive PCSK9 inhibitors, so the study does not settle whether earlier treatment improves longer-term outcomes. [1]

2.0 Key Points

  1. AMUNDSEN randomized 2,161 high-risk patients with STEMI or NSTEMI who were undergoing primary or urgent percutaneous coronary intervention, commonly called coronary stenting. [1]
  2. At six weeks, median LDL-C was 16 mg/dL with pre-procedure evolocumab and 56 mg/dL with standard care. [1]
  3. At 12 months, 82% of the evolocumab group and 40% of the standard-care group reached LDL-C below 55 mg/dL with at least a 50% reduction from baseline (adjusted odds ratio 5.54, 95% CI 4.50-6.82; p<0.001). [1]
  4. Death from any cause or unplanned cardiovascular hospitalization occurred in 14.6% and 15.4%, respectively (adjusted odds ratio 0.94, 95% CI 0.73-1.19; p=0.59). [1]
  5. The findings support rapid LDL-C goal attainment after acute MI, but do not support routine pre-procedure evolocumab solely to reduce one-year clinical events. [1]

3.0 Evidence base

AMUNDSEN enrolled 2,161 high-risk patients with ST-segment elevation or non-ST-segment elevation myocardial infarction across 48 sites in six countries. Participants were undergoing primary or urgent percutaneous coronary intervention. They received evolocumab 140 mg every two weeks for one year, beginning before the procedure, plus standard care, or standard care alone. Both groups received high-intensity lipid-lowering treatment, and PCSK9 inhibitors were allowed in the control group. [1]

The lipid result was clear. At six weeks, median LDL-C was 16 mg/dL with evolocumab and 56 mg/dL with standard care. By 12 months, 82% of patients assigned to evolocumab met the combined LDL-C goal of below 55 mg/dL and at least a 50% reduction from baseline, compared with 40% assigned to standard care. The adjusted odds ratio was 5.54 (95% CI 4.50-6.82; p<0.001). [1]

The clinical endpoint did not differ at one year. All-cause death or unplanned cardiovascular hospitalization occurred in 14.6% of the evolocumab group and 15.4% of the standard-care group (adjusted odds ratio 0.94, 95% CI 0.73-1.19; p=0.59). Serious adverse events were similar between groups. [1]

4.0 What the result means

The trial separates two questions that are often treated as one. Starting a PCSK9 inhibitor before coronary stenting can bring LDL-C down quickly and keep more patients at goal. That did not translate into fewer deaths or unplanned cardiovascular hospitalizations over the first year in this study. [1]

For patients and clinicians, the result does not argue against intensive LDL-C lowering after myocardial infarction. It argues against assuming that the timing of a very early injection, by itself, will reduce short-term events. Usual secondary-prevention care still includes prompt high-intensity statin therapy and a plan to reach LDL-C targets. The broader treatment framework is described in /clinical/05-treatment-pathways.html. [1]

5.0 What remains uncertain

The available source is an ACC expert analysis rather than the primary JAMA report. Follow-up was limited to one year, the control group could receive PCSK9 inhibitors, and the trial was not designed around hard atherosclerotic endpoints alone. These features limit what can be concluded about long-term benefit from very early treatment. [1]

EVOLVE-MI, which is enrolling 6,019 patients, may provide a clearer answer about whether early evolocumab after myocardial infarction improves longer-term cardiovascular outcomes. Until then, pre-procedure evolocumab may be reasonable for selected patients with very high LDL-C or likely barriers to follow-up, but AMUNDSEN does not establish it as routine care for preventing short-term events. [1]

This summary is provided for clinical decision support only and does not replace individualized clinical judgment. Findings are summarized from the cited primary sources; consult those sources before changing practice.

Version History

Version Date Description
1.0.0 2026-10-18 Initial release

References

  1. AMUNDSEN: Does Early Evolocumab Improve Outcomes in Acute MI?. https://www.acc.org/Latest-in-Cardiology/Articles/2026/10/09/15/06/AMUNDSEN.

© 2026 The Sandusky Dyslipidemia Model. For clinical decision support only. Not a substitute for clinical judgment.